Noxopharm (ASX:NOX) said BioRay Pharmaceutical found positive results as part of its investigation into the use of Noxopharm's oligonucleotides as targeted drugs in the context of antibody-drug conjugates, according to a Wednesday Australian bourse filing.
The results showed that conjugation to a specific Noxopharm oligonucleotide could be achieved and that the conjugated drug significantly improved the performance of one of BioRay's antibodies designed to target autoimmune disease, further reducing inflammation, represented by a key biological marker.
BioRay plans to conduct further studies with its drugs and Noxopharm's assets.
In 2024, Noxopharm signed a material transfer agreement with BioRay, which is active in China's biopharmaceutical industry.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.